MiNK Therapeutics financials
$12.26+1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.93 | $-2.86 | $-6.54 | $-8.30 | $-11.60 |
| EBITDA | -$12.5M | -$11.1M | -$22.7M | -$30.8M | -$28.3M |
| Operating cash flow | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Free cash flow | -$5.9M | -$9.6M | -$15.8M | -$19.1M | -$13.1M |
| Diluted shares | 4.3M | 3.8M | 3.4M | 3.4M | 2.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $13.4M | $4.6M | $3.4M | $19.6M | $38.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
| Total liabilities | $28.5M | $25.3M | $22.6M | $21.9M | $16.5M |
| Shareholders' equity | -$14.2M | -$19.6M | -$18.1M | -$401.3K | $23.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology